To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min From cancer to rare diseases ...

BioMarin Pharmaceutical ( (BMRN)) just unveiled an update. On December 19, 2025, BioMarin Pharmaceutical Inc., a biopharmaceutical company focused on therapies for rare genetic and metabolic diseases, ...

BioMarin BMRN-1.38%decrease; red down pointing triangle Pharmaceutical has struck a deal to buy fellow biotech Amicus Therapeutics FOLD 0.04%increase; green up pointing triangle for about $4.8 billion ...

Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Friday it would acquire Amicus Therapeutics (FOLD.O), opens new tab for about $4.8 billion, in the drugmaker's second deal ...

Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus Therapeutics, a company whose two commercialized products each offer ...

BioMarin Pharmaceutical said on ⁠Friday it would acquire Amicus ‍Therapeutics ‍for about $4.8 ‍billion, expanding its presence in rare metabolic diseases. The ‍drugmaker will ‍pay $14.50 per share for ...

BioMarin BMRN0.29%increase; green up pointing triangle Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics FOLD-1.00%decrease; red down pointing triangle for about ...

BioMarin Pharmaceutical (BMRN) has agreed to acquire rare disease drug developer Amicus Therapeutics (FOLD) in an all-cash transaction worth nearly $4.8B, the companies announced on Friday. The deal, ...

The all-cash acquisition price translates to $14.50 per share, valuing the offer at a 33% premium to Amicus's last close, a 46% premium to its 30-day average price, and a 58% premium to its 60-day ...

Matthew Herper covers medical innovation — both its promise and its perils. For BioMarin CEO Alexander Hardy, the Friday morning purchase of Amicus Therapeutics for $4.8 billion represents a ...